More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.69B
EPS
-0.86
P/E ratio
--
Price to sales
43.27
Dividend yield
--
Beta
1.147788
Previous close
$2.91
Today's open
$2.95
Day's range
$2.50 - $2.95
52 week range
$2.50 - $5.24
show more
CEO
Najat Khan
Employees
600
Headquarters
Salt Lake City, UT
Exchange
Nasdaq Global Select
Shares outstanding
622759259
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Why Recursion Pharmaceuticals Stock Is Up Today
One of Recursion Pharmaceuticals' internally developed drugs is advancing to late-stage clinical trials. While only aiming at a relatively small opportunity, Wednesday's announcement affirms the value of Recursion's AI-powered pre-clinical-testing solution.
The Motley Fool • 7 hours ago

Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though investors are watching for more detail.
The Motley Fool • 2 hours ago

Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through unbiased phenotypic screening using Recursion's AI foundation models.
GlobeNewsWire • 14 hours ago

Recursion to Participate in Upcoming Investor Conferences
Salt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced its participation in the following upcoming investor conferences: Jefferies Global Healthcare Conference London — Wednesday, November 18, 2026 Evercore 9th Annual Healthcare Conference — Monday, November 30, 2026 Citi's 2026 Global Healthcare Conference — Tuesday, December 1, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (Nasdaq: RXRX) is a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives.
GlobeNewsWire • Nov 11, 2026

2 healthcare stocks to turn $10 into $100 by next year
Healthcare stocks have emerged as an area of relative strength in 2026, outperforming technology shares as investors seek opportunities beyond the artificial intelligence (AI) boom.
Finbold • Nov 11, 2026

RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
Recursion highlights promising clinical data for REC-4881 and REC-1245, beats Q3 earnings estimates and extends its cash runway into 2029 through disciplined spending.
Zacks Investment Research • Nov 4, 2026

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call
Recursion Pharmaceuticals NASDAQ: RXRX reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor program REC-1245, partnership progress and an extension of its expected cash runway into 2029.
MarketBeat • Nov 3, 2026

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. ( RXRX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Najat Khan - CEO, President & Director Vicki Goodman - Chief Medical Officer Ben Taylor - CFO & President of Recursion UK Conference Call Participants Evelien Dekker Bryson Katona Jesse Laster Lindsay Huff Laura Laster Presentation Najat Khan CEO, President & Director Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from the CGA-IGC Annual Meeting in Denver.
Seeking Alpha • Nov 3, 2026

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.
Zacks Investment Research • Nov 3, 2026

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today reported financial results for the third quarter ended September 30, 2026, together with business updates highlighting continued clinical, pipeline and platform execution.
GlobeNewsWire • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Recursion Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.